SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is sharply declining, fueling widespread 'extreme fear' within the community and intensifying debates over its efficacy as a 'digital gold' store of value versus traditional assets. The drop is largely attributed to perceived market manipulation, significant institutional outflows, and ongoing political uncertainties regarding crypto regulation.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending after its earnings report, experiencing a notable sell-off driven by concerns over substantial AI-related capital expenditure and a slight deceleration in Azure cloud growth. The community widely views the significant price drop as an overreaction, creating a perceived buying opportunity, while some debate the immediate returns from its OpenAI investments.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics (CATX) is surging with high volume and landing on top trending lists, driven by a strong community belief in a short squeeze and momentum plays despite a lack of specific new fundamental news. While many celebrate its rapid ascent and speculate on higher price targets and potential buyouts, others caution about its history of volatility and question the underlying catalyst beyond trading dynamics.

TechCreate Group Ltd. - Ordinary Shares - Class A

TechCreate Group Ltd. (TCGL) is trending due to an explosive, multi-hundred percent price surge that has triggered multiple trading halts and fueled intense community discussion, with traders captivated by the dramatic run while also expressing caution and skepticism about its underlying drivers.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is heavily trending as its stock experiences continuous declines, exacerbated by a recent downgrade from a low-rated analyst, leading to widespread community frustration and accusations of market manipulation. Despite the bearish sentiment and leadership criticism, many investors believe the stock is severely undervalued given its strong fundamentals, aggressive share buybacks, and the upcoming earnings report next week which is seen as a potential catalyst for a significant rebound.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing a steep sell-off following its earnings report, despite beating estimates and announcing a substantial share buyback program, as broader market sentiment questions the growth prospects of software companies amid increasing AI competition. The community is actively debating if the decline is an overreaction or if concerns over compressed valuations and further downside are justified.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending after exceeding quarterly earnings and revenue expectations, coupled with robust guidance that is largely validating its substantial investments in AI, despite some market discussion questioning the scale of capital expenditures.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending ahead of its earnings report, with the community keenly divided on whether strong iPhone sales and the reported acquisition of AI startup Q.AI will outweigh concerns about rising memory costs and its AI strategy, as many view its results as a critical market catalyst.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending down sharply amid a broad crypto market decline, with Ethereum and Bitcoin facing significant selling pressure and community sentiment pointing to a "crypto winter." Investors are vocally criticizing CEO Tom Lee, accusing him of misleading predictions and stock dilution that has led to widespread losses and the belief that retail is serving as exit liquidity.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending as Bitcoin's significant price drop magnifies bearish sentiment, with community members expressing strong concerns over Saylor's dilution strategy and the company's valuation. Discussion centers on the stock's downside potential and questions about its leveraged bet on digital assets amidst broader crypto market weakness.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

Equity

<ul class="summary-bullets"><li>Shiong added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors.</li><li>Explaining what this means, he said that half of the patients at this stage do not survive beyond six months.</li><li>The Culver City, California-based immunotherapy company stated in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial.</li></ul>ImmunityBio Inc. (IBRX) shares were up more than 5% in Monday’s pre-market trade after a volatile session on Friday following the company’s Phase 2 glioblastoma trial update.The Culver City, California-based immunotherapy company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-volatility-after-immunitybio-phase-2-glioblastoma-trial-update/cmyR7VnR4gk">stated</a> in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial. The company said that as of Jan. 22, 2026, it had enrolled 23 patients in the Phase 2 glioblastoma trial, of which four deaths have been reported so far, while 14 patients have evaluable clinical data.<h2 class="st-heading-2">ImmunityBio Founder Issues Clarification</h2>However, Patrick Soon Shiong, ImmunityBio’s founder,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2015148449059201385">took</a> to X on Saturday to clarify what the update signified.“The fact that we have patients alive still at 12 months and that the ‘median has NOT YET&nbsp; been reached’ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care,” he said.He added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors. Explaining what this means, he said that half of the patients at this stage do not survive beyond the timeframe of six months or longer.<figure class="image"><img src="https://news.stocktwits-cdn.com/Patrick_post_jpg_65b0607bff.webp" alt="Dr. Pat Soon-Shiong's post on X" width="727" height="500"><figcaption>Dr. Pat Soon-Shiong's post on X | @DrPatrick/X</figcaption></figure><h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a> was in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user said that they believe IBRX should trade at a market capitalization of $10 billion, while adding that ImmunityBio represents a “complete shift in standard of care of cancer.” The company’s current market capitalization is $6.35 billion.<stembedurl>https://stocktwits.com/BixbyKnolls/message/642850960</stembedurl>Another user wondered why any investor would not hold the IBRX stock with “so many approvals on the horizon.”<stembedurl>https://stocktwits.com/Nate711/message/642846497</stembedurl><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 226% year-to-date and 107% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-silver-gold-price-rally-people-clueless-slv-gld-etf-soar-pre-market/cmy7FWpR4Wx">Peter Schiff Says Most People Are 'Clueless' And In For A 'Shock' As Gold, Silver Scale New Highs: SLV, GLD ETFs Soar Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

<ul class="summary-bullets"><li>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones.</li><li>Matrix-M adjuvant is a proprietary vaccine ingredient, used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets.</li><li>Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.</li></ul>Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market trading on Tuesday after the company signed a licensing agreement with Pfizer, granting the pharmaceutical giant non-exclusive rights to use Novavax’s Matrix-M adjuvant in up to two disease areas.Matrix-M adjuvant is a proprietary vaccine ingredient that improves the body’s immune response. It is made from naturally derived compounds and is used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets, according to Novavax.<h2 class="st-heading-2">What Is The Novovax-Pfizer Deal?</h2>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones. Novavax is also eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.Under the agreement, Pfizer will take full responsibility for the development and commercialization of its products, while Novavax will supply the Matrix-M adjuvant. The partnership strengthens Novavax’s long-term revenue potential.This comes after Novavax completed the transfer of U.S. and European marketing authorizations for its COVID-19 vaccine, Nuvaxovid, to Sanofi in November. The move resulted in a second $25 million milestone payment to Novavax, following the completion of the European Union marketing authorization transfer in October 2025.Novavax is expected to receive additional milestone payments and royalties tied to Nuvaxovid, Sanofi-developed combination products, and new vaccines that use Novavax’s Matrix-M adjuvant. Novavax also has long-standing partnerships with Japan’s Takeda and the Serum Institute of India.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> on Stocktwits remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes. NVAX was also among the top three trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/NVAX_jpg_1f4183eedd.webp" alt="NVAX.jpg">One bullish user said that the stock is undervalued.<stembedurl>https://stocktwits.com/ejaXstoXX/message/642272237</stembedurl>Another user was bullish about Matrix-M’s market potential.<stembedurl>https://stocktwits.com/P38FTD/message/642271830</stembedurl>The stock has declined around 6% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ivf-stock-soaring-premarket/cmUum0oR4ap">INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

<ul class="summary-bullets"><li>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa.</li><li>The company will also partner with regional pharmaceutical firm BioPharma Cigalah.</li><li>Enrolment for the QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter.</li></ul>ImmunityBio, Inc. (IBRX) drew retail attention on Wednesday as the stock jumped 8% after the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer.The approval marks a major regulatory milestone, adding to existing authorizations in the United States and the United Kingdom, as well as conditional approval in the European Union.“We are pleased to bring ANKTIVA to Saudi patients with NMIBC, who otherwise have no viable options but life-altering surgery,” said Rich Adcock, Chief Executive Officer, ImmunityBio.<h2 class="st-heading-2">ImmunityBio’s Expansion Plans</h2>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa. The company will also partner with regional pharmaceutical firm BioPharma Cigalah. Management cited the rising incidence of bladder and other cancers in the region as a key driver behind the strategy.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.<h2 class="st-heading-2">ANKTIVA Developments</h2>Beyond bladder cancer, ANKTIVA is also drawing attention for its broader oncology potential. <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-surge-today/cmUXXCjR4Ig">Recent clinical data</a> from the QUILT-2.023 and QUILT-3.055 trials in non-small cell lung cancer (NSCLC) showed improved immune recovery and extended survival when ANKTIVA was combined with checkpoint inhibitors.Responding patients achieved a median survival of up to 21.1 months, significantly outperforming traditional chemotherapy outcomes.Meanwhile, enrolment for the company’s QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter (Q2) of 2026 and a potential biologics license application (BLA) by the end of the year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around ImmunityBio remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_1a3db9b5f3.webp" alt="IBRX.jpg">One user speculated that the approval could double the product revenue for the company.<stembedurl>https://stocktwits.com/Bc3345/message/641787673</stembedurl>One user sees the stock climb to $5 in the short term and $15-25 in the medium term.<stembedurl>https://stocktwits.com/AshvsEvilDead/message/64178170</stembedurl><a href="https://stocktwits.com/AshvsEvilDead/message/641781706">6</a>Over the past year, <a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> have risen around 21%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-clsk-stock-rising-premarket-texas-data-centre-deal/cmULgA7R4e0">CLSK Stock Receives Premarket Boost On Texas Data Center Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval

The approval in Saudi Arabia follows authorizations in the U.S. and the U.K., as well as a conditional approval in the European Union.

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

<ul class="summary-bullets"><li>The company said that responding patients lived longer overall, with a median survival of 16.2 months.</li><li>The data come from two clinical trials, evaluating 151 patients across first-line and later-line treatment settings.</li><li>ImmunityBio is now advancing its Phase 3 trial, it said.</li></ul>ImmunityBio Inc. (IBRX) stock caught retail attention on Tuesday after the company reported positive clinical results showing its immunotherapy ANKTIVA significantly boosts immune function and improves survival in non-small cell lung cancer (NSCLC) patients when combined with checkpoint inhibitors.The data come from two clinical trials, QUILT-2.023 and QUILT-3.055, evaluating 151 patients across first-line and later-line treatment settings.<a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> were up 12.4% at the time of writing. Retail chatter increased to ‘high’ on Stocktwits while sentiment shifted to ‘extremely bullish’ from ‘bullish’ a day earlier.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_72f59b2252.webp" alt="IBRX.jpg">One bullish user expects the U.S. Food and Drug Agency (FDA) to approve ANKTIVA for NSCLC and expand access broadly.<stembedurl>https://stocktwits.com/svertical1/message/641645369</stembedurl>Another user sees the benefits of a non-chemotherapy treatment.<stembedurl>https://stocktwits.com/Armymike1981/message/641633526</stembedurl><h2 class="st-heading-2">Outcome Of The Trials</h2>In the first-line QUILT-2.023 study, patients receiving ANKTIVA plus a checkpoint inhibitor showed a statistically significant and sustained increase in absolute lymphocyte count (small white blood cell) compared with checkpoint inhibitor therapy alone. In the second- and later-line QUILT-3.055 study, 77% of patients maintained or restored healthy lymphocyte levels, showing ANKTIVA’s role as a lymphocyte-stimulating agent.The company said that responding patients lived longer overall, with a median survival of 16.2 months, while those with stronger immune recovery had a median survival of 21.1 months, far exceeding historical results with standard chemotherapy.ImmunityBio is now advancing its Phase 3 trial, comparing ANKTIVA plus checkpoint inhibitors to docetaxel in second-line NSCLC, it added.“The results from these studies support a potential paradigm shift toward what we define as Immunotherapy 2.0, which is the coordinated activation of the innate immune system through natural killer cells and the adaptive immune system through T cells to restore immune competence and extend survival,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.Over the past year, IBRX shares have gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-q4-revenue-beat-apple-card-reserve-hits-profit/cmUXEfbR44r">JPMorgan Beats Revenue Estimates In Q4 – A Record Quarter For Wealth Unit Offsets Apple Card Drag</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients

The company reported positive results with ANKTIVA, which boosted immune function and improved survival in NSCLC when combined with checkpoint inhibitors.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

<ul class="summary-bullets"><li>Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows.&nbsp;</li><li>Tradipitant previously failed in gastroparesis but is now under FDA review with labeling discussions underway.</li><li>Approval could open a motion-sickness market estimated at $670 million in 2025.</li></ul>Vanda Pharmaceuticals (VNDA) is facing a moment of reckoning as it awaits an FDA nod for its motion-sickness treatment candidate. After a so-so performance for much of the year, the&nbsp;<a href="https://stocktwits.com/symbol/VNDA">Vanda stock</a> rally kicked off in the middle of November and has been going strong ever since.&nbsp;Between Nov. 14 and Friday’s trading session, the stock has gained about 62%, wiping out the year's losses.<h2 class="st-heading-2">Binary Event Beckons</h2>More than 13 years after licensing NK-1R from Lilly (LLY) for a $1 million upfront payment—and over a year after the FDA rejected its application in gastroparesis—Vanda is once again knocking on the regulator’s door, this time seeking approval for motion sickness. Vand has since rechristened the drug candidate as tradipitant.&nbsp;Last September, the drug regulator issued a Complete Response Letter (CRL) to the new drug application (NDA) for tradipitant for treating symptoms of gastroparesis. A CRL is a letter stating that the agency will not approve a regulatory application in its current form.Reacting to the decision, Vanda said:<blockquote>“The CRL was conclusory in nature, generally disregarded the evidence provided and instead suggested that Vanda conduct additional studies with a design and duration inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding and natural course of the disorder.”</blockquote>Vanda has looked past the disappointment and is hoping for good news. Providing a regulatory update on tradipitant as a preventive treatment for motion sickness-induced vomiting in late November, Vanda stated that the Prescription Drug User Fee Act (PDUFA) target date of Dec. 30 for completion of the review remained unchanged. It also confirmed that the FDA recently issued comments on the proposed labeling and that labeling discussions have formally commenced. If approved, Vanda will have the distinction of delivering the first new pharmacologic treatment for motion sickness in over four decades.According to Mordor Intelligence, the total addressable opportunity for motion sickness is around $670 million in 2025. This is expected to grow at a 3.1% compounded annual growth rate (CAGR), reaching $781 million by 2030.Tradipitant earlier produced positive results in a study that evaluated it as a treatment option for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults.In other recent developments, Vanda announced in early December that the FDA had lifted the partial clinical hold on the tradipitant protocol, which had limited the doses that could be administered. This decision allows Vanda to extend clinical studies of tradipitant in motion sickness.In mid-December, the company said it had submitted a Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis (GPP). It expects to end the year with $260 million to $290 million in cash.&nbsp;Founded in 2003, Vanda focuses on new technologies, including genetics and genomics, for drug discovery, clinical trials, and commercial positioning. The company sells Hetlioz as a treatment for sleep-wake disorder, Fanapt, an antipsychotic medication, and Ponvory for relapsing multiple sclerosis. Vanda generates net product sales of $158.9 million for the first nine months of 2025, marking 9% year-over-year (YoY) growth.&nbsp;<h2 class="st-heading-2">Upcoming Catalysts</h2>Apart from the imminent FDA decision, the company has a slew of catalysts that can propel the stock higher if they pan out favorably. Key among the catalysts are:-FDA decision date for Feb. 21, 2026, for Bysanti (milsaperidone) NDA for bipolar I disorder and schizophrenia-Re-review of the supplemental NDA for Hetlioz for the treatment of jet lag disorder by Jan. 7, 2026<h2 class="st-heading-2">What Analysts and Retail Traders Feel About Vanda</h2>Initiating coverage of Vanda stock with a ‘Buy’ rating and a $11 price target in early November, B. Riley said Vanda is a commercial-stage turnaround story trading at a "historic discount,” the Fly reported. The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines,” the firm said.<img src="https://news.stocktwits-cdn.com/Vandas_Valuation_PS_png_bcec7dcc5c.webp" alt="Vandas_Valuation_PS.png">Source: Fiscal.aiOn Stocktwits, retail traders are ‘bullish’ about&nbsp;Vanda as of early Monday.<figure class="image"><img style="aspect-ratio:725/444;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_7_43_31_AM_png_814cfe36d5.webp" alt="Screenshot 2025-12-29 at 7.43.31 AM.png" width="725" height="444"></figure>&nbsp;A retail watcher was already bracing for $10+ level early this week,&nbsp;<a href="https://stocktwits.com/ms0632/message/640275096">anticipating</a> “good news.” Another user said that, irrespective of the FDA decision, the company has other sales and opportunities to limit downside. Citing “big upside potential,” they&nbsp;<a href="https://stocktwits.com/djacks/message/640216881">said</a> they added more shares.In premarket trading on Monday, the stock climbed over 4% to $7.35.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-outperformed-vs-nvidia-microsoft-ai-stocks-2025/cL75psZREDr">Palantir Crushed Nvidia, Microsoft And Most AI Stocks In 2025 — And Investors Didn’t Care About Valuation</a>

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock

Vanda’s shares have surged since mid-November ahead of a pivotal FDA decision on tradipitant for motion sickness, a binary event that could unlock a new market and drive further upside, with additional regulatory catalysts ahead.

Current Price	$173.88
Prev Close	$174.03
Open	$174.23
Dividend Yield	N/A
50-Day Moving Average	$170.67
Beta	N/A
Avg. Volume	1.54M
PE Ratio	N/A

52-Week High	$179.64
52-Week Low	$107.43
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF